US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) and privately-held Affinia Therapeutics have entered into a strategic research collaboration to engineer adeno-associated virus (AAV) capsids for the delivery of gene therapies.
Affinia’s AAV vector technology will be used in Vertex’ gene therapy efforts, with a focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF).
Bastiano Sanna, executive vice president and chief of cell and genetic therapies at Vertex, said: “This collaboration with Affinia Therapeutics will enhance our existing capabilities in discovering and developing transformative therapies for people with serious diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze